AndrewMartinBellingerMDPhD
Cardiology • Boston, MAPreventive Cardiology
Chief Scientific Officer, Verve Therapeutics; Co-founder, Lyndra Therapeutics Co-founder, Corner Therapeutics Cardiovascular Medicine, Brigham and Women's Hospital
Dr. Bellinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Division of Cardiology
Boston, MA 02115Phone+1 857-307-4000
Education & Training
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2011 - 2015
University of California (San Francisco)Residency, Internal Medicine, 2009 - 2011
Columbia University Vagelos College of Physicians and SurgeonsClass of 2009
Certifications & Licensure
MA State Medical License 2011 - 2026
Publications & Presentations
PubMed
- 54 citationsEfficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targetingin Nonhuman Primate and Mouse Models.Richard G Lee, Anne Marie Mazzola, Maurine C Braun, Colin Platt, Scott B Vafai
Circulation. 2023-01-17 - 297 citationsLeaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in miceStephan E. Lehnart, Marco Mongillo, Andrew M. Bellinger, Nicolas Lindegger, Bi-Xing Chen
The Journal of Clinical Investigation. 2008-06-02 - 393 citationsHypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle.Andrew M. Bellinger, Steven Reiken, Christian Carlson, Marco Mongillo, Xiaoping Liu
Nature Medicine. 2009-02-08
Press Mentions
A Single Infusion of a Gene-Editing Medicine May Control Inherited High LDL CholesterolNovember 12th, 2023- Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-Type and LDLR-Deficient Non-Human PrimatesMarch 3rd, 2023
- Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial ResultsNovember 7th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
